Through an integrated approach combining network pharmacology, molecular docking, in vivo experiments in MRL/lpr mice, and in vitro cellular models, we demonstrated that Hyp alleviates renal injury in LN by inhibiting the phosphorylation of AKT1, a key regulator of PANoptosis. The gene discussed is AKT1; the disease is lobular neoplasia.